On the heels of a pre-IND meeting with the FDA, Carmell Therapeutics said it is significantly advancing the company’s clinical and regulatory strategies driving the company’s need to expand its manufacturing facilities. Carmell is a biotech focused on the development and commercialization of regenerative medicine technologies, and will soon be conducting a Phase III clinical study for its first product/indication, bone healing accelerant, based on its core plasma-based bioactive m...